InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: frrol post# 106739

Wednesday, 05/31/2017 9:59:30 PM

Wednesday, May 31, 2017 9:59:30 PM

Post# of 461947
I don't know why Biogen, (at a minimum) would not be able to replicate the pre-clinical work on MS done my Prof. Lisak at Wayne State, presented at ACTRIMS, Feb. 2016.
http://www.anavex.com/sigma-1-receptor-agonists-inhibit-oligodendrocyte-cytotoxicity-induced-by-molecules-involved-in-cell-damage-in-multiple-sclerosis/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News